CRISPR Therapeutics AG [CRSP] Insider Activity: An Update for Investors

CRISPR Therapeutics AG’s recently made public that its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $3.03 million on Jan 29. In the deal valued at $60.51 per share,50,000 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 187,377 shares worth roughly $13.12 million.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Then, Kulkarni Samarth sold 20,000 shares, generating $1,250,058 in total proceeds. Upon selling the shares at $62.50, the Chief Executive Officer now owns 187,377 shares.

Before that, Kulkarni Samarth sold 25,000 shares. CRISPR Therapeutics AG shares valued at $1,621,894 were divested by the Chief Executive Officer at a price of $64.88 per share. As a result of the transaction, Kulkarni Samarth now holds 387,377 shares, worth roughly $27.12 million.

TD Cowen downgraded its CRISPR Therapeutics AG [CRSP] rating to an Underperform from a a Market perform in a research note published recently.

Price Performance Review of CRSP

On Friday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 1.71% to $70.01. Over the last five days, the stock has gained 8.12%. CRISPR Therapeutics AG shares have risen nearly 11.84% since the year began. Nevertheless, the stocks have risen 25.77% over the past one year. While a 52-week high of $76.97 was reached on 02/09/24, a 52-week low of $37.55 was recorded on 01/08/24. SMA at 50 days reached $64.42, while 200 days put it at $56.33. A total of 2.53 million shares were traded, compared to the trading of 1.98 million shares in the previous session.

Levels Of Support And Resistance For CRSP Stock

The 24-hour chart illustrates a support level at 68.75, which if violated will result in even more drops to 67.48. On the upside, there is a resistance level at 71.88. A further resistance level may holdings at 73.75. The Relative Strength Index (RSI) on the 14-day chart is 62.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.07, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 19.89%. Stochastics %K at 84.24% indicates the stock is a selling.

How much short interest is there in CRISPR Therapeutics AG?

A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on Jan 31, 2024, dropping by -0.51 million shares to a total of 15.74 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2023 was 16.25 million shares. There was a decline of -3.24%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 20.08% of the overall stock float, the days-to-cover ratio (short ratio) fell to 7.89.

Most Popular